- BriaCell stock (TSX:BCT) is positioned to the upside after reporting phase 2 survival data for its Bria-IMT cell therapy with checkpoint inhibitors, outperforming standard of care antibody-drug conjugates in hormone receptor positive metastatic breast cancer patients
- BriaCell Therapeutics is a clinical-stage biotechnology company developing cancer immunotherapies
- The cancer immunotherapy stock (TSX:BCT) last traded at C$5.32
BriaCell Therapeutics (TSX:BCT), a cancer immunotherapy stock, is positioned to the upside after reporting phase 2 survival data for its Bria-IMT cell therapy with checkpoint inhibitors, outperforming standard of care antibody-drug conjugates (ADC) in hormone receptor positive (HR+) metastatic breast cancer (MBC) patients.
The study enrolled 54 heavily pre-treated patients (median number of 6 prior treatments), 37 of which were treated with the Bria-IMT formulation being deployed in an ongoing phase 3 study under the U.S. Food and Drug Administration’s Fast Track Designation.
Data shows 25 of 37 patients in the phase 2 study achieved a median survival rate of 17.3 months, exceeding ADC standard of care Trodelvy’s 14.4 months in similar heavily pre-treated patients.
The survival rate in triple-negative breast cancer (TNBC) marked by the absence of estrogen, progesterone and human epidermal growth factor receptors approximated that of Trodelvy and came in 70 per cent higher than chemotherapy.
According to Wednesday’s news release, no Bria-IMT-related discontinuations have been reported to date.
Leadership insights
“We are truly impressed with the survival benefit data of the regimen that exceeds or meets those of Trodelvy in HR+ and TNBC metastatic breast cancer patients, respectively. Bria-IMT appears to be very well-tolerated,” William V. Williams, BriaCell’s president and chief executive officer, said in a statement. “We look forward to further confirming this clinical data in our ongoing pivotal phase 3 study with overall survival as its primary endpoint.”
“HR+ and TNBC metastatic breast cancer represent a significant proportion of the patient population and are the most difficult patient groups to treat. They have limited therapeutic options and overall survival of only a few months,” added Giuseppe Del Priore, BriaCell’s chief medical officer. “Our clinical data supports our hypothesis that the Bria-IMT regimen plus checkpoint inhibitors has the potential to address the unmet medical needs of HR+ and TNBC MBC patients and provide an effective and well-tolerated therapeutic option.”
About BriaCell Therapeutics
BriaCell is a clinical-stage biotechnology company developing cancer immunotherapies.
BriaCell stock (TSX:BCT) last traded at C$5.32.
Join the discussion: Find out what everybody’s saying about this cancer immunotherapy stock on the BriaCell Therapeutics Corp. Bullboard and check out Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
(Top photo: Adobe Stock)
